natgillin/translations-raw huggingface dataset:
It must not be used in patients with tumours of the pituitary gland or hypothalamus, or cancer of the breast, womb or ovary.
Ne sme se uporabljati pri bolnikih s tumorji hipofize ali hipotalamusa ali rakom na prsih, maternici ali jajčnikih.
GONAL-f is given to stimulate the ovaries to produce more than one egg at a time;
Zdravilo GONAL-f se daje za spodbujanje jajčnikov k izdelavi več kot enega jajčeca naenkrat;
GONAL-f is used to treat the following groups:
Zdravilo GONAL-f se uporablja pri naslednjih skupinah bolnikov:
• adult women with severe deficiency (very low levels) of luteinising hormone (LH) and follicle stimulating hormone (FSH).
• pri odraslih ženskah s hudim pomanjkanjem (zelo nizkimi ravnmi) luteinizirajočega hormona (LH) in folikle stimulirajočega hormona (FSH).
• adult women who are undergoing assisted reproductive techniques (fertility treatment) such as in-vitro fertilisation.
• pri odraslih ženskah, ki se zdravijo s postopki asistirane reprodukcije, kot je in vitro oploditev (zdravljenje neplodnosti).
In these studies, GONAL-f was compared with human FSH that had been extracted from urine.
V teh študijah so zdravilo GONAL-f primerjali s FSH, ki je bil izločen iz urina.
The active substance in GONAL-f, follitropin alfa, is a copy of the natural hormone FSH.
Zdravilna učinkovina zdravila GONAL-f, folitropin alfa, je kopija naravnega hormona FSH.
In the body, FSH controls reproductive function: in women, it stimulates the production of eggs; and in men, it stimulates the production of sperm in the testicles.
Hormon FSH v telesu nadzoruje funkcijo reprodukcije: pri ženskah spodbuja nastajanje jajčec, pri moških pa nastajanje semenčic v modih.
What is the risk associated with GONAL-f?
Kakšna tveganja so povezana z zdravilom GONAL-f?
GONAL-f is used together with human chorionic gonadotrophin (hCG) to stimulate sperm production.
Zdravilo GONAL-f se uporablja skupaj s humanim horionskim gonadotropinom (hCG) za spodbujanje nastanka sperme.
GONAL-f is a medicine that contains the active substance follitropin alfa.
GONAL-f je zdravilo, ki vsebuje zdravilno učinkovino folitropin alfa.
For the full list of all side effects reported with GONAL-f, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila GONAL-f, glejte navodilo za uporabo.
GONAL-f was effective in triggering egg development in women with severe LH and FSH deficiency.
Zdravilo GONAL-f je bilo učinkovito tudi pri sprožitvi nastajanja jajčec pri ženskah s hudim pomanjkanjem LH/FSH.
In the study in men, GONAL-f, used in combination with hCG, was effective in stimulating sperm production, with 63% of the men starting to produce sperm.
V študiji pri moških je bilo zdravilo GONAL-f v kombinaciji s hCG pri 63 % moških učinkovito pri spodbujanju nastajanja sperme.
GONAL-f was also as effective as human FSH at stimulating the ovaries during assisted reproductive techniques.
Zdravilo GONAL-f je bilo enako učinkovito kot humani FSH pri spodbujanju jajčnikov med postopki asistirane reprodukcije.
Why has GONAL-f been approved?
Zakaj je bilo zdravilo GONAL-f odobreno?
In women, GONAL-f must not be used when there is enlargement of an ovary or a cyst that is caused by something other than polycystic ovarian disease, or when there is unexplained bleeding from the vagina.
Pri ženskah se ne sme uporabljati ob povečanih jajčnikih ali prisotnosti cist, ki niso posledica policističnega obolenja jajčnikov, ali pri nepojasnjenem krvavenju iz nožnice.
GONAL-f is given together with a medicine containing LH to stimulate the eggs to mature in the ovaries;
Zdravilo GONAL-f se daje skupaj z zdravili, ki vsebujejo LH, kar spodbudi jajčeca, da dozorijo v jajčnikih;
In women, ovarian cysts (sacs of fluid within the ovaries) and headache are also seen in more than 1 patient in 10.
Pri več kot 1 ženski od 10 je bilo opaziti tudi nastanek ovarijskih cist (vrečic s tekočino v jajčnikih) in glavobol.
The full EPAR for GONAL-f can be found here.
Celotno javno poročilo o oceni zdravila (EPAR) za zdravilo GONAL-f je na voljo tukaj.
What is GONAL-f used for?
Za kaj se zdravilo GONAL-f uporablja?
What is GONAL-f?
Kaj je zdravilo GONAL-f?
The follitropin alfa in GONAL-f is produced by a method known as ‘recombinant DNA technology': it is made by a cell that has received a gene (DNA), which makes it able to produce human FSH.
Folitropin alfa v zdravilu GONAL-f je izdelan z metodo, imenovano „tehnologija rekombinantne DNK“.
GONAL-f was as effective as human FSH in women who did not produce eggs or respond to clomiphene citrate: 84% of the women receiving GONAL-f produced eggs, compared with 91% of those receiving human FSH.
Jajčeca so začela nastajati pri 84 % žensk, ki so prejemale zdravilo GONAL-f, v primerjavi z 91 % tistih, ki so prejemale humani FSH.
How has GONAL-f been studied?
Kako je bilo zdravilo GONAL-f raziskano?
How is GONAL-f used?
Kako se zdravilo GONAL-f uporablja?
How does GONAL-f work?
Kako zdravilo GONAL-f deluje?
The dose is adjusted to give the best control.
Odmerek se prilagodi tako, da se doseže najboljši možni nadzor.
It is available as round tablets (blue: 0.5 mg; yellow: 1 mg; peach: 2 mg).
Na voljo je v obliki okroglih tablet (modre barve: 0,5 mg; rumene barve: 1 mg; breskove barve: 2 mg).
Repaglinide Teva repaglinide EPAR summary for the public
Repaglinid Teva repaglinid Povzetek EPAR za javnost
Repaglinide Teva is taken before meals, normally up to 15 minutes before each main meal.
Zdravilo Repaglinid Teva se jemlje pred obroki, ponavadi največ 15 minut pred vsakim glavnim obrokom.
This means that Repaglinide Teva is similar to a ‘reference medicine' already authorised in the European Union (EU) called NovoNorm.
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu NovoNorm.
Other information about Repaglinide Teva:
Druge informacije o zdravilu Repaglinid Teva:
If patients are transferred from another anti-diabetes medicine, the recommended starting dose is 1 mg.
Pri bolnikih, ki preidejo z drugega zdravila za sladkorno bolezen, je priporočeni začetni odmerek 1 mg.
What are the benefit and risk of Repaglinide Teva?
Kakšne so koristi in tveganja, povezana z zdravilom Repaglinid Teva?
The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Repaglinide Teva has been shown to have comparable quality and to be bioequivalent to NovoNorm.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Repaglinid Teva primerljivo raven kakovosti kot zdravilo NovoNorm ter da mu je biološko enakovredno.
Repaglinide Teva is a ‘generic medicine'.
Repaglinid Teva je „generično zdravilo“.
Because Repaglinide Teva is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.
Ker je Repaglinid Teva generično zdravilo in je biološko enakovredno referenčnemu zdravilu, se šteje, da ima enake koristi in tveganja kot referenčno zdravilo.
Repaglinide Teva is a medicine that contains the active substance repaglinide.
Repaglinid Teva je zdravilo, ki vsebuje zdravilno učinkovino repaglinid.
The Committee recommended that Repaglinide Teva be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Repaglinid Teva odobri dovoljenje za promet.
A doctor should regularly test the patient's blood glucose to find the lowest effective dose.
Raven bolnikove glukoze v krvi mora zdravnik redno preverjati, da določi najmanjši učinkoviti odmerek.
Because Repaglinide Teva is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine (this means that the two medicines produce the same levels of the active substance in the body).
Ker je zdravilo Repaglinid Teva generično zdravilo, so bile študije omejene na preskuse, s katerimi se dokazuje, da je biološko enakovredno referenčnemu zdravilu (tj. da zdravili dosegata enake ravni zdravilne učinkovine v telesu).
Therefore, the CHMP's view was that, as for NovoNorm, the benefit outweighs the identified risk.
Zato je CHMP menil, da njegove koristi, tako kot pri zdravilu NovoNorm, odtehtajo znana tveganja.
Repaglinide Teva is used in patients who have type 2 diabetes (non-insulin-dependent diabetes).
Zdravilo Repaglinid Teva se uporablja pri bolnikih s sladkorno boleznijo tipa 2 (sladkorno boleznijo, ki ni odvisna od insulina).
Type 2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively.
Sladkorna bolezen tipa 2 je bolezen, pri kateri trebušna slinavka ne proizvaja dovolj insulina za vzdrževanje primerne ravni glukoze v krvi ali pri kateri telo insulina ne more učinkovito izrabljati.
It is used together with diet and exercise to lower blood glucose (sugar) levels in patients whose hyperglycaemia (high blood glucose levels) cannot be controlled by diet, weight reduction and exercise.
Uporablja se skupaj z dieto in telesno dejavnostjo za znižanje glukoze (sladkorja) v krvi pri bolnikih, pri katerih hiperglikemije (visoke koncentracije glukoze v krvi) ni več mogoče nadzorovati z dieto, zmanjšanjem telesne mase in telesno dejavnostjo.
The European Commission granted a marketing authorisation valid throughout the European Union for Repaglinide Teva to Teva Pharma B.V. on 29 June 2009.
Evropska komisija je dovoljenje za promet z zdravilom Repaglinid Teva, veljavno po vsej Evropski uniji, odobrila družbi Teva Pharma B.V.
Repaglinide Teva can also be used for type 2 diabetes patients whose blood glucose levels are usually controlled well on diet, but are experiencing temporary loss of blood glucose control.
Zdravilo Repaglinid Teva se lahko uporabi tudi pri bolnikih s sladkorno boleznijo tipa 2, pri katerih so ravni glukoze v krvi ponavadi dobro nadzorovane z dieto, vendar doživljajo obdobja prehodne izgube nadzora.
Why has Repaglinide Teva been approved?
Zakaj je bilo zdravilo Repaglinid Teva odobreno?
Repaglinide Teva helps the pancreas to produce more insulin at mealtimes and is used to control type 2 diabetes.
Zdravilo Repaglinid Teva spodbuja trebušno slinavko, da v času obrokov tvori več insulina, zato se uporablja za nadzor sladkorne bolezni tipa 2.
Repaglinide Teva may also be used with metformin (another anti-diabetes medicine) in type 2 diabetes patients whose blood glucose levels are not satisfactorily controlled on metformin alone.
Zdravilo Repaglinid Teva se lahko uporabi tudi z metforminom (drugim zdravilom za sladkorno bolezen) pri bolnikih s sladkorno boleznijo tipa 2, pri katerih samo z metforminom ne moremo zadovoljivo nadzorovati ravni glukoze v krvi.
The full EPAR for Repaglinide Teva can be found here.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Repaglinide Teva je na voljo tukaj.
How has Repaglinide Teva been studied?
Kako je bilo zdravilo Repaglinid Teva raziskano?
What is Repaglinide Teva?
Kaj je zdravilo Repaglinid Teva?
What is Repaglinide Teva used for?
Za kaj se zdravilo Repaglinid Teva uporablja?
How is Repaglinide Teva used?
Kako se zdravilo Repaglinid Teva uporablja?
How does Repaglinide Teva work?
Kako zdravilo Repaglinid Teva deluje?
Adults and adolescents can use any form of the medicine.
Odrasli in mladostniki lahko uporabljajo katero koli farmacevtsko obliko.
The European Commission granted a marketing authorisation valid throughout the European Union for Aerius on 15 January 2001.
Evropska komisija je dovoljenje za promet z zdravilom Aerius, veljavno po vsej Evropski uniji, odobrila dne 15. januarja 2001.
The full EPAR for Aerius can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Aerius je na voljo na spletni strani agencije : ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Other information about Aerius
Druge informacije o zdravilu Aerius
This is a summary of the European public assessment report (EPAR) for Aerius.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Aerius.
Additional studies were presented to show that the syrup, oral solution and orodispersible tablets are treated by the body in the same way as the tablets, and to show that they can be used safely in children.
Predstavili so tudi dodatne študije, da se dokaže, da se sirup, peroralna raztopina in orodisperzibilne tablete v telesu presnavljajo enako kot tablete, in da se dokaže, da se lahko varno uporabijo pri otrocih.
Aerius has also been studied in 416 patients with urticaria.
Zdravilo Aerius so proučevali tudi pri 416 bolnikih z urtikarijo.
For more information about treatment with Aerius, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Aerius preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
What benefit has Aerius shown during the studies?
Kakšne koristi je zdravilo Aerius izkazalo med študijami?
In all studies, the effectiveness of Aerius was compared with that of placebo (a dummy treatment).
V vseh študijah so učinkovitost zdravila Aerius primerjali s placebom (zdravilom brez zdravilne učinkovine).
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Aerius.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Aerius, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Aerius is a medicine containing the active substance desloratadine.
Aerius je zdravilo, ki vsebuje zdravilno učinkovino desloratadin.
Aerius has been studied in a total of eight studies involving about 4,800 adult and adolescent patients with allergic rhinitis (including four studies in seasonal allergic rhinitis, and two studies in patients who also had asthma).
Zdravilo Aerius so raziskali v osmih študijah, v katerih je sodelovalo približno 4 800 odraslih in mladostnikov z alergijskim rinitisom (vključno s štirimi študijami sezonskega alergijskega rinitisa in dvema študijama pri bolnikih, ki so imeli tudi astmo).
What is the risk associated with Aerius?
Kakšna tveganja so povezana z zdravilom Aerius?
In the two studies in urticaria, the decrease in symptom score after six weeks of treatment with Aerius was 58 and 67%, compared with 40 and 33% in placebo-treated patients.
V dveh študijah pri bolnikih z urtikarijo se je število simptomov po šestih tednih zdravljenja z zdravilom Aerius zmanjšalo za 58 % in 67 % v primerjavi s 40 % in 33 % pri bolnikih, ki so prejemali placebo.
Aerius must not be used in people who are hypersensitive (allergic) to desloratadine, loratadine or any of the other ingredients.
Zdravila Aerius ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) desloratadin, loratadin ali katero koli drugo sestavino zdravila.
The active substance in Aerius, desloratadine, is an antihistamine.
Zdravilna učinkovina zdravila Aerius, desloratadin, je antihistaminsko zdravilo.
For the full list of all side effects reported with Aerius, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Aerius, glejte navodilo za uporabo.
Why has Aerius been approved?
Zakaj je bilo zdravilo Aerius odobreno?
Aerius is used to relieve the symptoms of allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) or urticaria (a skin condition caused by an allergy, with symptoms including itching and hives).
Zdravilo Aerius se uporablja za lajšanje simptomov alergijskega rinitisa (vnetja nosne votline, ki ga povzroči alergija, na primer seneni nahod ali alergija na pršice) ali urtikarije (bolezni kože, ki jo povzroča alergija in katere simptomi vključujejo srbenje in izpuščaje).
The CHMP decided that Aerius's benefits are greater than its risks for the relief of symptoms associated with allergic rhinitis or urticaria and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Aerius pri lajšanju simptomov alergijskega rinitisa ali urtikarije večji od z njim povezanih tveganj, in priporočil da se zanj odobri dovoljenje za promet.
In allergic rhinitis, looking at the results of all studies taken together, two weeks of treatment with 5 mg Aerius led to an average decrease in symptom score of 25 to 32%, compared with a decrease of 12 to 26% in the patients receiving placebo.
Dvotedensko zdravljenje z zdravilom Aerius 5 mg je pri alergijskem rinitisu v vseh študijah privedlo do zmanjšanja števila simptomov za povprečno 25 % do 32 %, v primerjavi z 12- do 26-odstotnim zmanjšanjem pri bolnikih, ki so prejemali placebo.
For children from one to five years of age, the dose is 1.25 mg once a day, taken as 2.5 ml syrup or oral solution.
Otroci, ki so stari od 1 do 5 let, prejemajo odmerek 1,25 mg enkrat na dan v obliki 2,5 ml sirupa ali peroralne raztopine.
For children from six to 11 years of age, the dose is 2.5 mg once a day, taken either as 5 ml of the syrup or oral solution, or as one 2.5 mg orodispersible tablet.
Otroci, stari od 6 do 11 let, pa prejemajo odmerek 2,5 mg enkrat dnevno v obliki 5 ml sirupa ali peroralne raztopine oziroma z eno 2,5-miligramsko orodisperzibilno tableto.
The effectiveness of Aerius was measured by looking at the change in the symptoms (nasal discharge, itching, sneezing and congestion) before and after two or four weeks of treatment.
Učinkovitost zdravila Aerius so merili s spremembo simptomov (izcedek iz nosu, srbenje, kihanje, zamašenost nosu), ki so jih opazovali pred zdravljenjem in 2 do 4 tedne po zaključku zdravljenja.
How does Aerius work?
Kako zdravilo Aerius deluje?
How has Aerius been studied?
Kako je bilo zdravilo Aerius raziskano?
What is Aerius used for?
Za kaj se zdravilo Aerius uporablja?
What is Aerius?
Kaj je zdravilo Aerius?
How is Aerius used?
Kako se zdravilo Aerius uporablja?
-1- - Synthetic peptide analogue of GnRF conjugated to a carrier protein of min. 300 µg per 2 ml dose
-1- Sintetični peptidni analog GnRF konjugiran na nosilni protein, najmanj 300 µg na 2 ml odmerka
Pharmaceutical form
Farmacevts ka oblika
Content Package size
Velikost pakiranja Karenca
Withdrawal period
Vsebina
Date of first authorisation: 16 December 1998 Date of last renewal: 16 December 2008
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM Datum prve odobritve: 16. december 1998 Datum zadnjega podaljšanja: 16. december 2008
It is important that you take Micardis every day until your doctor tells you otherwise.
Pomembno je, da jemljete zdravilo Micardis vsak dan, dokler vam zdravnik ne naroči drugače.
CLINICAL PARTICULARS 4.1 Therapeutic indications Hypertension
KLINIČNI PODATKI 4.1 Terapevtske indikacije Hipertenzija
This applies especially to the medicines listed below taken at the same time with Micardis:
To velja zlasti za spodaj našteta zdravila, kadar jih jemljete hkrati z zdravilom Micardis:
Your doctor will normally advise you to stop taking Micardis before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Micardis.
Zdravnik vam bo praviloma svetoval, da zdravilo Micardis prenehate jemati, preden boste zanosili ali takoj ko boste vedeli, da ste noseči, in vam svetoval, da namesto zdravila Micardis jemljete drugo zdravilo.
See also information under the heading “Do not take Micardis”.
Glejte tudi informacije pod naslovom “Ne jemljite zdravila Micardis”.
What Micardis is and what it is used for
Kaj je zdravilo Micardis in za kaj ga uporabljamo
Take it as soon as you remember then carry on as before.
Vzemite ga takoj, ko se spomnite in z jemanjem nadaljujte kot običajno.
There are no adequate data from the use of Micardis in pregnant women.
Ni zadostnih podatkov o uporabi zdravila Micardis pri nosečnicah.
Patients with rare hereditary problems of fructose intolerance should not take Micardis.
Bolniki z redko dedno intoleranco za fruktozo ne smejo jemati zdravila Micardis.
The listing also takes into account serious adverse reactions and adverse reactions leading to discontinuation reported in three clinical long-term studies including 21,642 patients treated with telmisartan for the reduction of cardiovascular morbidity for up to six years.
V seznamu so zajeti tudi resni neželeni dogodki in neželeni dogodki, zaradi katerih je bilo treba zdravljenje prekiniti, o katerih so poročali v treh dolgotrajnih kliničnih študijah pri skupno 21.642 bolnikih, ki so telmisartan do šest let jemali za zmanjševanje pojavnosti srčnožilnih bolezni.
Micardis contains sorbitol.
Zdravilo Micardis vsebuje sorbitol.
Children and adolescents The use of Micardis in children and adolescents up to the age of 18 years is not recommended.
Otroci in mladostniki Uporabe zdravila Micardis pri otrocih in mladostnikih do 18. leta starosti ne priporočamo.
If you have the impression that the effect of Micardis is too strong or too weak, talk to your doctor or pharmacist.
Če menite, da je učinek zdravila Micardis premočan ali prešibak, se posvetujte z zdravnikom ali s farmacevtom.
If you forget to take Micardis
Če ste pozabili vzeti zdravilo Micardis
The safety and efficacy of Micardis in children and adolescents aged below 18 years have not been established.
Varnost in učinkovitost zdravila Micardis pri otrocih in mladostnikih, mlajših od 18 let, še nista bili dokazani.
Micardis is used to treat essential hypertension (high blood pressure) in adults.
Zdravilo Micardis uporabljamo za zdravljenje esencialne hipertenzije (visokega krvnega tlaka) pri odraslih.
Other medicines and Micardis
Druga zdravila in zdravilo Micardis
• If you are taking an ACE-inhibitor or aliskiren (see also information under the headings “Do not take Micardis” and “Warning and precautions”).
• zaviralec ACE ali aliskiren (glejte tudi informacije pod naslovoma "Ne jemljite zdravila Micardis" in "Opozorila in previdnostni ukrepi"),
You should consult with your doctor if you need to adjust the dose of your other medicine while taking Micardis.
Z zdravnikom se morate posvetovati, ali je treba med jemanjem zdravila Micardis prilagoditi odmerek vašega drugega zdravila.
What you need to know before you take Micardis
Kaj morate vedeti, preden boste vzeli zdravilo Micardis
Do not take Micardis
Ne jemljite zdravila Micardis
Insomnia, depression Anxiety
nespečnost, depresija
The effect of Micardis may be reduced when you take NSAIDs (non steroidal anti-inflammatory medicines, e.g. aspirin or ibuprofen) or corticosteroids.
Učinek zdravila Micardis se lahko zmanjša, če jemljete nesteroidna protivnetna zdravila (na primer aspirin ali ibuprofen) ali kortikosteroide.
Micardis is also used to reduce cardiovascular events (i.e. heart attack or stroke) in adults who are at risk because they have a reduced or blocked blood supply to the heart or legs, or have had a stroke or have high risk diabetes.
Zdravilo Micardis uporabljamo tudi za zmanjševanje srčnožilnih dogodkov (npr. srčnega napada ali možganske kapi) pri odraslih z velikim tveganjem zaradi zmanjšane ali blokirane oskrbe srca ali nog s krvjo, ali pri odraslih, ki so doživeli možgansko kap ali imajo sladkorno bolezen z velikim tveganjem.
14 tablets 28 tablets 56 tablets 98 tablets
14 tablet 28 tablet 56 tablet 98 tablet
Talk to your doctor before taking Micardis if you are suffering or have ever suffered from any of the following conditions or illnesses:
Pred začetkom jemanja zdravila Micardis se posvetujte z zdravnikom, če imate ali ste kadar koli v preteklosti imeli katero od naslednjih stanj ali bolezni:
Remove your Micardis tablet from the blister only directly prior to intake.
Tableto zdravila Micardis vzemite iz pretisnega omota tik, preden jo boste zaužili.